About C4 Therapeutics:
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Job Summary
C4 Therapeutics is seeking an enthusiastic, scientifically motivated Senior Scientist to join the DNA Encoded Library (DEL) Technology team within the Lead Discovery group. In this role, you will play a significant role in the implementation of our bespoke DEL platform utilized for identification of MonoDAC (molecular glue) degraders. Your background in DEL Selection design and data analysis, along with familiarity with targeted protein degradation will allow you to drive the technical and intellectual refinement and development of the MonoDAC DEL platform.
Your Role
Your Background
Required:
Preferred:
Compensation
The base pay range for this position at commencement of employment is expected to be between $158,460 and $175,140 annually; however, base pay offered may vary depending on multiple individualized factors, including job-related knowledge, skills, and experience.
C4 Therapeutics is an Equal Opportunity Employer.
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.
Take the next step in your career journey